Once the additional validation and optimization steps are accomplished, we foresee that SMI-6 could provide a triple benefit to BC patients with PRL/PRLR-expressing tumors: suppression of tumor growth, inhibition of invasion/metastasis, and enhanced efficacy of standard chemotherapeutic agents. This evidence concerns the gene PRLR and neoplasm.